CJC-1295 vs Tesamorelin: What Researchers Need to Know in 2026
CJC-1295 and tesamorelin are both growth hormone-releasing hormone (GHRH) analogs studied for their effects on growth hormone secretion, but they work differently and have distinct research profiles. If your lab is deciding between these two compounds — or considering stacking them — here’s what the literature and current research community consensus tell us.
Quick Comparison
| Feature | CJC-1295 | Tesamorelin |
|---|---|---|
| Classification | Synthetic GHRH analog (modified GRF 1-29) | Synthetic GHRH analog (full 44-amino acid) |
| Half-Life | ~30 min (no DAC) / ~8 days (with DAC) | ~26 minutes |
| GH Release Pattern | Pulsatile (no DAC) or sustained (with DAC) | Pulsatile, mirrors natural rhythm |
| FDA Status | Research compound only | FDA-approved (Egrifta) for lipodystrophy |
| Primary Research Focus | GH secretion, body composition, tissue response | Visceral adipose tissue (research focus) |
| Typical Research Pairing | Often paired with ipamorelin (GHRP) | Studied as standalone compound |
| Amino Acid Length | 29 amino acids (modified) | 44 amino acids (trans-3-hexenoic acid modification) |
How CJC-1295 Works
CJC-1295 is a modified version of growth hormone-releasing factor (GRF 1-29) with amino acid substitutions at positions 2, 8, 15, and 27 that protect it from enzymatic degradation. This modification extends its functional window beyond natural GHRH, which is degraded within minutes in plasma.
The compound exists in two forms that researchers should distinguish clearly:
CJC-1295 (no DAC) — also called Modified GRF 1-29 or “Mod GRF”
This version has a half-life of approximately 30 minutes and produces discrete GH pulses. It’s the form most commonly paired with ghrelin receptor agonists like ipamorelin in research protocols because the pulsatile release pattern more closely mimics the body’s natural GH secretion rhythm.
CJC-1295 with DAC (Drug Affinity Complex)
The DAC modification allows the peptide to bind to albumin in circulation, extending its half-life to approximately 8 days. This creates a sustained, non-pulsatile elevation in growth hormone. The extended half-life simplifies exposure schedules in research settings, but some researchers prefer the no-DAC version because the continuous GH elevation pattern diverges from physiological norms.
How Tesamorelin Works
Tesamorelin is a synthetic analog of the full 44-amino acid human GHRH sequence with a trans-3-hexenoic acid group attached to the tyrosine at position 1. This modification increases the peptide’s stability and potency compared to native GHRH while preserving the natural pulsatile release pattern.
What makes tesamorelin unique in this space is its FDA approval. It was approved in 2010 under the brand name Egrifta specifically for the reduction of excess abdominal fat (lipodystrophy) in HIV-positive trial participants. This means tesamorelin has a clinical evidence base that most research peptides lack — controlled trials, published safety data, and documented efficacy for at least one specific indication.
Published research on tesamorelin has shown significant reductions in visceral adipose tissue (trunk fat) without corresponding changes in peripheral adipose tissue, improvements in triglyceride levels and cholesterol ratios, cognitive-marker research (including models of mild cognitive impairment), and stimulation of endogenous GH secretion in a pattern that preserves the natural feedback loop.
Key Differences for Researchers
1. GH Release Pattern
CJC-1295 (no DAC) and tesamorelin both produce pulsatile GH release, but CJC-1295 with DAC produces sustained elevation. For research protocols concerned with maintaining physiological GH patterns, tesamorelin or CJC-1295 without DAC are generally preferred.
2. Evidence Base
Tesamorelin has the strongest clinical evidence of the two, with multiple Phase III trials, FDA approval, and ongoing research into metabolic and cognitive applications. CJC-1295 has a substantial body of preclinical and research-community evidence but fewer formal clinical trials.
3. Specificity of Action
Tesamorelin’s research has centered on visceral fat reduction and metabolic parameters. CJC-1295 research tends to focus more broadly on GH secretion, body composition, tissue response, and the synergistic effects when paired with GH secretagogues like ipamorelin or hexarelin.
4. Practical Considerations
CJC-1295 (no DAC) is typically studied in more frequent exposure schedules. Published tesamorelin studies follow the exposure schedule used in its registration trials. CJC-1295 with DAC’s extended half-life allows for less frequent administration but with the trade-off of non-pulsatile GH elevation.
The core distinction: Tesamorelin is the compound with the strongest clinical validation and a specific, FDA-backed indication for visceral fat reduction. CJC-1295 (especially the no-DAC form paired with ipamorelin) is the more versatile research tool for studying pulsatile GH secretion across broader applications.
Can They Be Stacked?
Some research protocols combine GHRH analogs with ghrelin receptor agonists (GHRPs) to amplify GH release synergistically. The most common research combination in this category is CJC-1295 (no DAC) + ipamorelin, which combines GHRH-pathway stimulation with ghrelin-pathway stimulation for a compounded pulse.
Stacking CJC-1295 with tesamorelin would be redundant in most research contexts — both act on the GHRH receptor. Researchers typically choose one GHRH analog and pair it with a compound from a different pathway if synergistic effects are the goal.
Which One Should Your Lab Study?
Choose CJC-1295 (no DAC) if your research focuses on pulsatile GH secretion, tissue response, general body composition, or synergistic protocols with ipamorelin.
Choose CJC-1295 with DAC if your research focuses on sustained GH elevation and less frequent administration in research models, and the departure from pulsatile release isn’t a concern.
Choose tesamorelin if your research focuses on visceral adipose tissue, metabolic markers, lipid profiles, or cognitive-related GH pathways. Its FDA approval and published clinical data provide a stronger evidence framework for grant applications and institutional review.
Research-grade peptides with batch-specific COAs
More research guides: Read our CJC-1295 & Ipamorelin Research Guide, our Tesamorelin Research Guide, or browse the full Complete Guide to Research Peptides 2026.